215 related articles for article (PubMed ID: 33859327)
1. Epigenetic alteration contributes to the transcriptional reprogramming in T-cell prolymphocytic leukemia.
Tian S; Zhang H; Zhang P; Kalmbach M; Lee JH; Ordog T; Hampel PJ; Call TG; Witzig TE; Kay NE; Klee EW; Slager SL; Yan H; Ding W
Sci Rep; 2021 Apr; 11(1):8318. PubMed ID: 33859327
[TBL] [Abstract][Full Text] [Related]
2. Genes encoding members of the JAK-STAT pathway or epigenetic regulators are recurrently mutated in T-cell prolymphocytic leukaemia.
López C; Bergmann AK; Paul U; Murga Penas EM; Nagel I; Betts MJ; Johansson P; Ritgen M; Baumann T; Aymerich M; Jayne S; Russell RB; Campo E; Dyer MJ; Dürig J; Siebert R
Br J Haematol; 2016 Apr; 173(2):265-73. PubMed ID: 26917488
[TBL] [Abstract][Full Text] [Related]
3. Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia.
Kiel MJ; Velusamy T; Rolland D; Sahasrabuddhe AA; Chung F; Bailey NG; Schrader A; Li B; Li JZ; Ozel AB; Betz BL; Miranda RN; Medeiros LJ; Zhao L; Herling M; Lim MS; Elenitoba-Johnson KS
Blood; 2014 Aug; 124(9):1460-72. PubMed ID: 24825865
[TBL] [Abstract][Full Text] [Related]
4. Noncanonical effector functions of the T-memory-like T-PLL cell are shaped by cooperative TCL1A and TCR signaling.
Oberbeck S; Schrader A; Warner K; Jungherz D; Crispatzu G; von Jan J; Chmielewski M; Ianevski A; Diebner HH; Mayer P; Kondo Ados A; Wahnschaffe L; Braun T; Müller TA; Wagle P; Bouska A; Neumann T; Pützer S; Varghese L; Pflug N; Thelen M; Makalowski J; Riet N; Göx HJM; Rappl G; Altmüller J; Kotrová M; Persigehl T; Hopfinger G; Hansmann ML; Schlößer H; Stilgenbauer S; Dürig J; Mougiakakos D; von Bergwelt-Baildon M; Roeder I; Hartmann S; Hallek M; Moriggl R; Brüggemann M; Aittokallio T; Iqbal J; Newrzela S; Abken H; Herling M
Blood; 2020 Dec; 136(24):2786-2802. PubMed ID: 33301031
[TBL] [Abstract][Full Text] [Related]
5. SAMHD1 is recurrently mutated in T-cell prolymphocytic leukemia.
Johansson P; Klein-Hitpass L; Choidas A; Habenberger P; Mahboubi B; Kim B; Bergmann A; Scholtysik R; Brauser M; Lollies A; Siebert R; Zenz T; Dührsen U; Küppers R; Dürig J
Blood Cancer J; 2018 Jan; 8(1):11. PubMed ID: 29352181
[TBL] [Abstract][Full Text] [Related]
6. Micro-RNA networks in T-cell prolymphocytic leukemia reflect T-cell activation and shape DNA damage response and survival pathways.
Braun T; Glass M; Wahnschaffe L; Otte M; Mayer P; Franitza M; Altmüller J; Hallek M; Hüttelmaier S; Schrader A; Herling M
Haematologica; 2022 Jan; 107(1):187-200. PubMed ID: 33543866
[TBL] [Abstract][Full Text] [Related]
7. B and T cell prolymphocytic leukaemia.
Cross M; Dearden C
Best Pract Res Clin Haematol; 2019 Sep; 32(3):217-228. PubMed ID: 31585622
[TBL] [Abstract][Full Text] [Related]
8. Computational gene expression analysis reveals distinct molecular subgroups of T-cell prolymphocytic leukemia.
Mikhaylenko N; Wahnschaffe L; Herling M; Roeder I; Seifert M
PLoS One; 2022; 17(9):e0274463. PubMed ID: 36129940
[TBL] [Abstract][Full Text] [Related]
9. T-cell prolymphocytic leukemia is associated with deregulation of oncogenic microRNAs on transcriptional and epigenetic level.
Patil P; Hillebrecht S; Chteinberg E; López C; Toprak UH; Seufert J; Bernhart SH; Kretzmer H; Bergmann AK; Bens S; Högel J; Müller A; Jebaraj BM; Schrader A; Johansson P; Costa D; Schlesner M; Dürig J; Herling M; Campo E; Stilgenbauer S; Wiehle L; Siebert R
Genes Chromosomes Cancer; 2022 Jul; 61(7):432-436. PubMed ID: 35218115
[TBL] [Abstract][Full Text] [Related]
10. T-Cell Prolymphocytic Leukemia: Diagnosis, Pathogenesis, and Treatment.
Gutierrez M; Bladek P; Goksu B; Murga-Zamalloa C; Bixby D; Wilcox R
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569479
[TBL] [Abstract][Full Text] [Related]
11. Reconstruction of rearranged T-cell receptor loci by whole genome and transcriptome sequencing gives insights into the initial steps of T-cell prolymphocytic leukemia.
Patil P; Cieslak A; Bernhart SH; Toprak UH; Wagener R; López C; Wiehle L; Bens S; Altmüller J; Franitza M; Scholz I; Jayne S; Ahearne MJ; Scheffold A; Jebaraj BMC; Schneider C; Costa D; Braun T; Schrader A; Campo E; Dyer MJS; Nürnberg P; Dürig J; Johansson P; Böttcher S; Schlesner M; Herling M; Stilgenbauer S; Macintyre E; Siebert R
Genes Chromosomes Cancer; 2020 Apr; 59(4):261-267. PubMed ID: 31677197
[TBL] [Abstract][Full Text] [Related]
12. T-cell prolymphocytic leukemia: an aggressive T cell malignancy with frequent cutaneous tropism.
Magro CM; Morrison CD; Heerema N; Porcu P; Sroa N; Deng AC
J Am Acad Dermatol; 2006 Sep; 55(3):467-77. PubMed ID: 16908353
[TBL] [Abstract][Full Text] [Related]
13. Prolymphocytic Leukemia: New Insights in Diagnosis and in Treatment.
Collignon A; Wanquet A; Maitre E; Cornet E; Troussard X; Aurran-Schleinitz T
Curr Oncol Rep; 2017 Apr; 19(4):29. PubMed ID: 28324286
[TBL] [Abstract][Full Text] [Related]
14. Genetic characterization of T-PLL reveals two major biologic subgroups and JAK3 mutations as prognostic marker.
Stengel A; Kern W; Zenger M; Perglerová K; Schnittger S; Haferlach T; Haferlach C
Genes Chromosomes Cancer; 2016 Jan; 55(1):82-94. PubMed ID: 26493028
[TBL] [Abstract][Full Text] [Related]
15. JAK/STAT-Activating Genomic Alterations Are a Hallmark of T-PLL.
Wahnschaffe L; Braun T; Timonen S; Giri AK; Schrader A; Wagle P; Almusa H; Johansson P; Bellanger D; López C; Haferlach C; Stern MH; Dürig J; Siebert R; Mustjoki S; Aittokallio T; Herling M
Cancers (Basel); 2019 Nov; 11(12):. PubMed ID: 31766351
[TBL] [Abstract][Full Text] [Related]
16. Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia.
Staber PB; Herling M; Bellido M; Jacobsen ED; Davids MS; Kadia TM; Shustov A; Tournilhac O; Bachy E; Zaja F; Porkka K; Hoermann G; Simonitsch-Klupp I; Haferlach C; Kubicek S; Mayerhoefer ME; Hopfinger G; Jaeger U; Dearden C
Blood; 2019 Oct; 134(14):1132-1143. PubMed ID: 31292114
[TBL] [Abstract][Full Text] [Related]
17. T-Cell Prolymphocytic Leukemia With t(X;14)(q28;q11.2): A Clinicopathologic Study of 15 Cases.
Hu Z; Medeiros LJ; Xu M; Yuan J; Peker D; Shao L; Tang Z; Mai B; Thakral B; Rios A; Hu S; Wang W
Am J Clin Pathol; 2023 Apr; 159(4):325-336. PubMed ID: 36883805
[TBL] [Abstract][Full Text] [Related]
18. Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL.
Schrader A; Crispatzu G; Oberbeck S; Mayer P; Pützer S; von Jan J; Vasyutina E; Warner K; Weit N; Pflug N; Braun T; Andersson EI; Yadav B; Riabinska A; Maurer B; Ventura Ferreira MS; Beier F; Altmüller J; Lanasa M; Herling CD; Haferlach T; Stilgenbauer S; Hopfinger G; Peifer M; Brümmendorf TH; Nürnberg P; Elenitoba-Johnson KSJ; Zha S; Hallek M; Moriggl R; Reinhardt HC; Stern MH; Mustjoki S; Newrzela S; Frommolt P; Herling M
Nat Commun; 2018 Feb; 9(1):697. PubMed ID: 29449575
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.
Andersson EI; Pützer S; Yadav B; Dufva O; Khan S; He L; Sellner L; Schrader A; Crispatzu G; Oleś M; Zhang H; Adnan-Awad S; Lagström S; Bellanger D; Mpindi JP; Eldfors S; Pemovska T; Pietarinen P; Lauhio A; Tomska K; Cuesta-Mateos C; Faber E; Koschmieder S; Brümmendorf TH; Kytölä S; Savolainen ER; Siitonen T; Ellonen P; Kallioniemi O; Wennerberg K; Ding W; Stern MH; Huber W; Anders S; Tang J; Aittokallio T; Zenz T; Herling M; Mustjoki S
Leukemia; 2018 Mar; 32(3):774-787. PubMed ID: 28804127
[TBL] [Abstract][Full Text] [Related]
20. T-cell prolymphocytic leukemia frequently shows cutaneous involvement and is associated with gains of MYC, loss of ATM, and TCL1A rearrangement.
Hsi AC; Robirds DH; Luo J; Kreisel FH; Frater JL; Nguyen TT
Am J Surg Pathol; 2014 Nov; 38(11):1468-83. PubMed ID: 25310835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
